FORM 8-K

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of Earliest event Reported): December 31, 2014

 

TARGETED MEDICAL PHARMA, INC.
(Exact name of registrant as specified in its charter)

 

DELAWARE   000-53071   20-5863618
(State or other jurisdiction of
incorporation or organization)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

2980 BEVERLY GLEN CIRCLE, SUITE 301
LOS ANGELES, CA 90077
(Address of principal executive offices)

 

(310) 474-9808
(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

[  ]   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
[  ]   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
[  ]   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
[  ]   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 
 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The Employment Agreement dated November 28, 2011 (the “Employment Agreement”) between Dr. David Silver and Targeted Medical Pharma, Inc. (the “Company”) expired on December 31, 2014 (the “Separation Date”).

 

On December 11, 2014, Dr. Silver notified the Company that if an agreement was not reached for continuation of his employment, then he intended to resign his position as President and Chief Operating Officer. Despite efforts by the Company and Dr. Silver to reach an agreement over the terms of his employment agreement, the parties were unable to reach an agreement. Dr. Silver completed his duties until December 31, 2014. Dr. Silver’s departure was not as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

 

2
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: January 6, 2015

 

  TARGETED MEDICAL PHARMA, INC.
     
  By: /s/ William E. Shell
  Name: William E. Shell, MD
  Title: Chief Executive Officer

 

3